In this video, Susana M. Campos, MD, MPH, discusses results from a phase 2 trial of pembrolizumab and lenvatinib for patients with recurrent or persistent clear-cell ovarian cancer.Findings from the ...

A grandad with advanced lung cancer which often leaves patients dead within four months has become free of the disease after ...

Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in ...

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...

A new research paper was published in Volume 16 of Oncotarget on June 10, 2025, titled "Exceptional responders to ...

The global Biosimilars Market, valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to advance at a resilient ...

In a new collaboration that could transform how cancer is treated, OCCAM Immune-a Mount Sinai initiative focused on ...

The global Biosimilars Market, valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...

Like a lot of people, I’d had some squamous cell carcinomas removed from my scalp. But in June, 2024, a red splotch, about the size of my fist, appeared on ...